MNDL Bio
Optimization of Gene Expression using Computational Approaches
Company Overview
Snapshot
Founded in June 2023 by Steve Grun, Eran Miller, and Tamir Tuller, MNDL Bio operates with 1–10 employees. The company has raised $2.1 million across two funding rounds from two investors. In January 2024, MNDL Bio secured funding from lead investor Earth &.
Business overview
MNDL Bio develops solutions for optimizing gene expression in cells to enhance protein production yield. The company leverages Artificial Intelligence (AI) and Machine Learning (ML) based on genomic Big Data, utilizing advanced algorithms and patented methods. MNDL Bio's technology aims to increase the efficiency and cost-effectiveness of biological systems, with applications spanning various sectors including alternative protein sources, precision fermentation for sustainable biofuels, and bio-based materials like bioplastics. The company operates within the Health Tech & Life Sciences sector, with relevance to climate tech through its focus on reducing greenhouse gas emissions and promoting environmental sustainability.
Strategic signal
In March 2025, MNDL Bio received an award for the most innovative biotech solution in the Middle East, highlighting the company's emerging leadership and validation within the regional biotech landscape. This recognition signals strong potential for market penetration and technological impact, positioning MNDL Bio as a key innovator in gene optimization and sustainable biological production.
Log in to access full profile ›Company Intelligence Q&A
- What is MNDL Bio's core technology?
- MNDL Bio utilizes Artificial Intelligence (AI) and Machine Learning (ML) based on genomic Big Data, employing advanced algorithms and patented methods to optimize gene expression in cells, thereby increasing protein production yield.
- When was MNDL Bio founded and by whom?
- MNDL Bio was founded in June 2023 by Steve Grun, Eran Miller, and Tamir Tuller.
- What was a significant recent achievement for MNDL Bio?
- In March 2025, MNDL Bio won an award for the most innovative biotech solution in the Middle East, recognizing its contributions to the sector.
- Which accelerator program did MNDL Bio participate in?
- In April 2025, MNDL Bio participated in the Intel-backed Ignite startup program in Israel, which kicked off its first cohort.
- What is MNDL Bio's relevance to climate tech?
- MNDL Bio's solutions contribute to climate tech by facilitating cost-effective production of alternative protein sources, enhancing precision fermentation for sustainable biofuels, and enabling the creation of bio-based materials like bioplastics, all of which aim to reduce greenhouse gas emissions and promote environmental sustainability.